Valeant’s board may be weighing whether pneumonia-stricken CEO J. Michael Pearson is ready to return to work. But he’d better return eventually, one analyst says–or the company could find itself in a world of hurt.
The way Nomura’s Shibani Malhotra sees it, the board “may not be comfortable with Pearson returning to the helm.” But if they replace him, the “loss of Pearson as a leader may remove much of the company’s competitive advantage,” she wrote to clients Thursday.
In that scenario, Valeant would “ideally need to replace him with an outsider with extensive pharmaceutical experience,” she believes–a description current interim CEO Howard Schiller, a former CFO at the company, doesn’t match. And if Valeant can’t come up with an outsider pharma vet? “We think the board could choose a more drastic approach and consider selling all or parts of the company,” she wrote.
Thursday, sources told CNBC that Pearson–who went on medical leave Dec. 28–was ready to return to work, but that Valeant’s board was debating whether he should. The report followed Valeant’s announcement from earlier this week that it would restate earnings after an ad hoc committee found $58 million in accounting mistakes related to controversial specialty pharmacy Philidor.
Questions around Pearson’s employment have been swirling since the Philidor drama was in full swing, with a short-seller in October accusing the drugmaker of using the pharmacy to inflate its top line. Those accusations, along with the price-hike uproar that enveloped the drugmaker as Congress demanded justification over increases on Valeant’s heart meds, sent shares–at their all-time high over the summer–into turmoil.
Through it all, though, Valeant has stood by its skipper. “Mike remains focused on running the business,” Valeant told Bloomberg in November. “Valeant’s core business remains strong and is well positioned for growth.”
By Carly Helfand
Source: Fierce Pharma
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
